Stonepine Capital Management’s MaxCyte MXCT Stock Holding History

Stonepine Capital Management’s Portfolio MXCT Stock Details MXCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$924K	Sell	751,606 -253,067	-25%	-$252K	0.52%	45
2026 Q1	$706K	Buy	1,004,673 +535,655	+114%	+$500K	0.28%	47
2025 Q4	$727K	Buy	469,018 +10,000	+2%	+$16K	0.53%	43
2025 Q3	$725K	Buy	+459,018	New	+$798K	0.59%	32
2023 Q4	–	Sell	-3,761,640	Closed	-$11.7M	–	20
2023 Q3	$11.7M	Sell	3,761,640 -205,276	-5%	-$825K	3.9%	7
2023 Q2	$18.2M	Buy	3,966,916 +1,259,826	+47%	+$5.79M	6.57%	6
2023 Q1	$13.4M	Buy	2,707,090 +2,433,803	+891%	+$12M	4.49%	7
2022 Q4	$1.49M	Buy	+273,287	New	+$1.68M	0.63%	16

Other funds holding MXCT

CFM

Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return

Vitruvian Partners London, United Kingdom $201M AUM 10.44% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Mudita Advisors London, United Kingdom $481M AUM 73.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BFM

Brooklands Fund Management London, United Kingdom $128M AUM

BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

CCM

Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return

PLC

Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Stonepine Capital Management's MXCT Position: Q2 2026 in Review

Stonepine Capital Management reduced its MaxCyte (MXCT) stake by 25% in Q2 2026, selling an estimated $252K and leaving 751,606 shares worth $924K. The position accounts for 0.52% of the portfolio, ranked #45.

Stonepine Capital Management first reported a position in MXCT in Q4 2022 and has held it in 8 quarters since. The position peaked at $18.2M in Q2 2023. 123 funds tracked by Wall St. Rank hold MXCT as of Q2 2026.

Stonepine Capital Management held 751,606 shares of MaxCyte worth $924K as of Q2 2026.
Stonepine Capital Management sold 253,067 MaxCyte shares in Q2 2026, an estimated $252K.
MaxCyte made up 0.52% of Stonepine Capital Management's portfolio in Q2 2026, its #45 holding.
Stonepine Capital Management first reported a position in MaxCyte in Q4 2022 and has held it in 8 quarters since.
Stonepine Capital Management's MaxCyte position peaked at $18.2M in Q2 2023.
123 funds tracked by Wall St. Rank held MaxCyte as of Q2 2026.

Based on Stonepine Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.